Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Urothelial Carcinoma Clinical Trial

— CabUC  

Official title:

Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Progressed After Cisplatin-based Chemotherapy and Anti-PD-1/PD-L1 Therapy or After Anti-PD-1/PD-L1 Therapy Only.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04066595
• Other study ID #: CabUC
• Status: Terminated
• Phase: Phase 2
• Start date: February 10, 2020
• Est. completion date: July 1, 2021

Study information

• Verified date: August 2021
• Source: Johannes Gutenberg University Mainz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this Phase II study we investigate the benefit of cabozantinib treatment for patients with locally advanced or metastasized urothelial cell carcinoma who have been pre-treated with checkpoint inhibitors only (cohort 1) or who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (cohort 2). We are lacking adequate response and outcome data in patients after immunotherapy and consider that this study will improve future treatment modalities for this important patient cohort.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: July 1, 2021
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Ability of subject to understand nature, importance and individual consequences of clinical trial.

2. Signed and dated informed consent of the subject must be available before start of any specific trial procedures.

3. Male or female patients = 18 years

4. Life expectancy = 10 weeks, by judgment of the Investigator.

5. Patients must be able to swallow intact tablets.

6. Patients with histology/cytology confirmed urothelial carcinoma (UC) including mixed pathology with predominantly UC, with locally advanced (T4b) or metastatic (lymph node or visceral) UC arising from bladder or upper urinary tracts. Patients with measurable disease (at least one tumor lesion measurable on radiographic imaging as defined by RECIST 1.1).

7. ECOG (Eastern Cooperative Oncology Group) Performance Status 0-1.

8. Cohort 1: patients who have been pre-treated with checkpoint inhibitors only for one of the following reasons: glomerular filtration rate more =30 ml/min and = 60 ml/min (Cockcroft-Gault formula), grade 2 or higher hearing loss or peripheral neuropathy. Cohort 2: patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors.

9. Recurrence within 12 months (by RECIST criteria version 1.1) from last cycle of chemotherapy or PD-1/PD-L1 therapy.

10. Recovery to baseline or = Grade 1 CTCAE v.5.0 from toxicities related to any prior treatments, unless the side effects are clinically non-significant and/or stable on supportive therapy.

Exclusion criteria:

1. Radiation, chemotherapy, or other anti-cancer therapy < 4 weeks prior to enrollment in the study.

2. Patients previously treated with small molecule tyrosine kinase inhibitors.

3. Systemic treatment with radionuclides < 4 weeks prior to enrollment in the study, and subjects with clinically relevant ongoing complications from prior radiation therapy.

4. Abdominal surgery <10 weeks prior to enrollment in the study. Complete wound healing must be observed at least 10 days prior to enrollment, and patients should not have relevant ongoing complications at study enrollment.

5. Inadequate organ and bone marrow function as evidenced by:

1. Hemoglobin <9.0 g/dL;

2. HbA1c > 8%;

3. Absolute neutrophil count <1.5 x 109/L;

4. Platelet count <100 x 109/L;

5. Fasting serum triglycerides > 2.5 x ULN and total cholesterol > 300 mg/dL. Lipid-lowering medication is allowed;

6. AST (aspartate aminotransferase) /SGOT (serum glutamate oxaloacetate transaminase) and/or ALT (alanine aminotransferase)/SGPT (serum glutamate pyruvate transaminase) =3.0 x ULN (upper limit of normal);

7. Total bilirubin >1.5 x ULN (upper limit of normal), for subjects with Gilbert's disease > 3 mg/dL;

8. Serum creatinine >2.0 x ULN;

9. Creatinine clearance = 30 mL/min (Cockroft-Gault formula);

10. PT (prothrombin time) or INR (international normalized ratio) or PTT (partial thromboplastin time) = 1.3 x ULN.

11. Urine protein-to-creatinine ratio (UPCR) > 1 mg/mg (> 113.2 mg/mmol)

6. Symptomatic brain metastases or leptomeningeal disease (in case of clinical suspicion of central nervous system involvement confirmed by existing CT or MRI scan of the brain).

7. History of another neoplasm except non-metastatic melanoma skin cancers, carcinoma in situ of the cervix, treated patients with incidental prostate cancer (pT2 (after RPE), Gleason = 6) and PSA (prostate specific antigen) = 0.5 ng/mL, or cancer cured by surgery, small field radiation or chemotherapy <5 years prior to enrollment.

8. History of inflammatory bowel disease, significant bowel obstruction, GI disorder with a high risk of perforation or fistula.

9. Any of the following events within 6 months prior to inclusion: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft surgery, clinically symptomatic and uncontrolled cardiovascular disease, or clinically significant arrhythmias (grade 3-4).

10. Concurrent treatment with strong inhibitors of cytochrome P450 3A4 (including but not limited to cyclosporin, erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil, St John's wort, rifampicin) or patients planning to receive these treatments. For patients who were receiving treatment with such agents, a one-week washout period is required prior to enrollment.

11. Currently receiving any other investigational agent or received an investigational agent within 30 days (or within 5 times the half-life of this agent) before the first dose of cabozantinib.

12. Significant allergy to a pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient.

13. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.

14. Active substance abuse (including active alcohol abuse).

15. Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial.

16. Women who are pregnant or breastfeeding.

17. Women of childbearing potential (WOCBP, a woman is considered of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal (defined as spontaneous amenorrhea for at least a year) or permanently sterilized (e.g. bilateral oophorectomy, hysterectomy, bilateral salpingectomy)), unless they have a negative serum or urine pregnancy test within 7 days prior to first dose of cabozantinib. The minimum sensitivity of the pregnancy test must be 25 IU/L or equivalent units of HCG (human chorionic gonadotropin).

18. Women of childbearing potential, unless they agree to practice a highly effective and medically accepted contraception method during trial and for 4 months after last dose of study drug. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as:

1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

• oral

• intravaginal

• transdermal

2. progestogen-only hormonal contraception associated with inhibition of ovulation:

• oral

• injectable

• implantable

3. intrauterine device (IUD)

4. intrauterine hormone-releasing system (IUS)

5. bilateral tubal occlusion

6. vasectomized partner (medical assessment must be present and done)

7. sexual abstinence when this is in line with the preferred and usual lifestyle of the subject

19. Sexually active male subjects, unless they agree to use contraception (condom, contraception for non-pregnant WOCBP partner) with their partners throughout the study and for 4 months after last dose of study drug and agree to inform the Investigator if the respective partner becomes pregnant during this time.

Related Conditions & MeSH terms

• Carcinoma
• Urothelial Carcinoma

Intervention

Drug:
• Cabozantinib
60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.

Locations

Country	Name	City	State
Germany	Department of Urology of the University Medical Center Mainz	Mainz

Sponsors (2)

Lead Sponsor	Collaborator
Johannes Gutenberg University Mainz	Interdisciplinary Center Clinical Trials (IZKS), University Medical Center Mainz

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate after 6 months of cabozantinib treatment	The response rate is defined as the percentage of subjects with a confirmed reduction in tumor size compared to baseline as well as fulfilling the criteria for complete or partial response according to RECIST 1.1. The response to treatment is measured by computer tomography (CT) every 12 weeks starting from the first day of cabozantinib treatment.	6 months
Secondary	Progression-free survival (PFS)	PFS is defined as the time from first intake of trial medication to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm.	Through study completion, up to approximately 2 years
Secondary	1-year survival	Rate of subjects surviving for at least one year after first intake/dose of trial medication	1 year
Secondary	Overall survival	The time between first application of trial medication to date of death due to any cause	Through study completion, up to approximately 2 years
Secondary	Clinical benefit rate	Complete or partial response or stable disease for = 6 months according to RECIST 1.1	Through study completion, up to approximately 2 years
Secondary	Response duration	Duration of response in months from the first response (CR or PR) to progress after first intake of treatment medication	Through study completion, up to approximately 2 years
Secondary	Number of Participants with Adverse Events (AEs)	An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.	Through study completion, up to approximately 2 years
Secondary	Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)	The number of participants who discontinue study treatment due to an AE will be presented.	Through study completion, up to approximately 2 years